Congenital Heart Futures Reauthorization Act of 2017

Bill 115 hr 1222, also known as the Congenital Heart Futures Reauthorization Act of 2017, is a piece of legislation that aims to reauthorize and improve programs and research related to congenital heart disease.

Congenital heart disease is a condition that affects the structure and function of the heart and is present at birth. It is the most common type of birth defect, affecting approximately 1 in every 100 babies born in the United States.

The bill seeks to continue funding for the Centers for Disease Control and Prevention's National Congenital Heart Disease Surveillance System, which collects data on the prevalence and impact of congenital heart disease. This data is crucial for understanding the scope of the problem and developing effective prevention and treatment strategies. Additionally, the bill aims to support research on congenital heart disease through the National Institutes of Health and the Health Resources and Services Administration. This research is essential for improving outcomes for individuals with congenital heart disease and developing new treatments. Overall, the Congenital Heart Futures Reauthorization Act of 2017 is an important piece of legislation that seeks to improve the lives of individuals with congenital heart disease through continued funding for research and surveillance programs.